Authors: LAZAR G OLAH T SZENDRENYI V SZENTPALI K BALOGH A

Citation: G. Lazar et al., THE VALUE OF SURGERY IN ESOPHAGEAL PERFORATIONS, British Journal of Surgery, 85, 1998, pp. 183-183

Authors: SZENTPALI K SZENDRENYI V OLAH T LAZAR T BALOGH A

Citation: K. Szentpali et al., EFFECTIVITY OF ENDOSCOPIC ESOPHAGEAL INTUBATION IN THE PALLIATION FORADVANCED, ESOPHAGUS CANCERS, British Journal of Surgery, 85, 1998, pp. 184-184

Authors: SCIBERRAS DG POLVINO WJ GERTZ BJ CHENG HY STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HTID AGONIST (VOL 43, PG 49, 1997), British journal of clinical pharmacology, 43(4), 1997, pp. 450-450

Authors: SCIBERRAS DG POLVINO WJ GERTZ BJ CHENG HY STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: Dg. Sciberras et al., INITIAL HUMAN-EXPERIENCE WITH MK-462 (RIZATRIPTAN) - A NOVEL 5-HT1D AGONIST, British journal of clinical pharmacology, 43(1), 1997, pp. 49-54

Authors: OLAH T REGELY K MANDI Y

Citation: T. Olah et al., THE INHIBITORY EFFECTS OF ALLOPURINOL ON THE PRODUCTION AND CYTOTOXICITY OF TUMOR-NECROSIS-FACTOR, Naunyn-Schmiedeberg's archives of pharmacology, 350(1), 1994, pp. 96-99

Authors: POLVINO W SCIBERRAS D GERTZ B CHENG H STEPANAVAGE M WITTREICH J OLAH T EDWARDS M MANT T

Citation: W. Polvino et al., MK-462 - 1ST HUMAN-EXPERIENCE WITH A NOVEL 5-HT1D AGONIST, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 129-129